Synergistic antitumor activities of docetaxel and octreotide associated with apoptotic-upregulation in castration-resistant prostate cancer.
Androgen deprivation therapy has become the fist-line treatment of metastatic prostate cancer; however, progression to castrate resistance disease occurs in the majority of patients. Thus, there is an urgent need for improvements in therapy for castration-resistant prostate cancer. The aims of the p...
Main Authors: | Sha Zhu, Judith Apondi Oremo, Sanqiang Li, Minghui Zhen, Yue Tang, Ying Du |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3954761?pdf=render |
Similar Items
-
Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
by: İlkay Gültürk, et al.
Published: (2022-11-01) -
Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
by: Hui-Li Wong, et al.
Published: (2015-06-01) -
Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
by: Nicholas D. James, et al.
Published: (2022-11-01) -
Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells
by: Irin Tanaudommongkon, et al.
Published: (2020-07-01) -
Abiraterone-Docetaxel scheduling for metastatic castration-resistant prostate cancer based on evolutionary dynamics.
by: Atefeh Deris, et al.
Published: (2023-01-01)